GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
4.4k
c/compounding·posted 2 years ago by u/chidi_demir

does telehealth actually matter or is it forum lore at this point

Discussion Cold Box ×2 Slow Clap ×3 Well Actually ×1

Genuine question, and the title is the question: does telehealth actually matter or is it forum lore at this point.

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.

Ask me anything specific. Anything general I will probably get wrong.

4,868 up / 448 down92% upvoted47 commentsid iwdnwj11 May 2024

47 comments

13 in this archive, depth 4

best — the order this archive was captured in

u/liv_vukovic704 points·2 years ago

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

replysharereportpermalink
u/hugo_bergstrom344 points·2 years ago

A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.

replysharereportpermalink
u/cold_chromatogram31101 points·2 years ago

the pharmacy and the prescriber are two separate questions

replysharereportpermalink
u/chidi_demirOP-3 points·2 years ago

Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.

replysharereportpermalink
u/kavya_kravchenko1 point·2 years ago

the price difference is mostly the intake, not the vial

replysharereportpermalink
u/hamza_serrano383 points·2 years ago

Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.

replysharereportpermalink
[removed]274 points·2 years ago

[removed by moderator]

replysharereportpermalink
u/bilal_osei168 points·2 years ago·edited

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

replysharereportpermalink
u/vikram_mbeki84 points·2 years ago

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

replysharereportpermalink
u/priya_palacios84 points·2 years ago

ask what the beyond-use date is based on

replysharereportpermalink
u/camila_mensa224 points·2 years ago

salt forms are the recurring argument and the answer is boring

replysharereportpermalink
u/solene_eriksen101 points·2 years ago·edited

salt forms are the recurring argument and the answer is boring

Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.

replysharereportpermalink
u/mikkel_correia171 points·2 years ago

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.